Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | Tofacitinib | 0.3 | uM | 1 | IFN-a2 | 44.0 | 67 | ||||
N2586 | IKK16 | 2.0 | uM | 1 | IFN-a2 | 39.5 | 40 | ||||
N2586 | JNK-IN-8 | 3.0 | uM | 1 | IFN-a2 | 44.0 | 33 | ||||
RA2159 | EGF | 100 | ng/mL | 1 | IFN-a2 | 24.0 | 58 | ||||
RA2159 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 1 | IFN-a2 | 21.0 | 60 | |
RA2159 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | IFN-a2 | 18.0 | 71 | |
RA2159 | Ruxolitinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | IFN-a2 | 22.0 | 53 | |
RA2159 | Tofacitinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | IFN-a2 | 20.5 | 58 | |
RA2159 | IKK16 | 2.0 | uM | EGF | 100 | ng/mL | 1 | IFN-a2 | 21.0 | 83 | |
RA2159 | JNK-IN-11 | 0.3 | uM | 1 | IFN-a2 | 22.0 | 65 | ||||
N2586 | EGF | 100 | ng/mL | 1 | IFN-a2 | 55.0 | 58 | ||||
N2586 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 1 | IFN-a2 | 55.0 | 63 | |
N2586 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | IFN-a2 | 41.0 | 51 | |
N2586 | Ruxolitinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | IFN-a2 | 49.0 | 74 | |
N2586 | Tofacitinib | 0.3 | uM | EGF | 100 | ng/mL | 1 | IFN-a2 | 53.0 | 60 | |
N2586 | IKK16 | 2.0 | uM | EGF | 100 | ng/mL | 1 | IFN-a2 | 45.0 | 52 | |
N2586 | JNK-IN-11 | 0.3 | uM | 1 | IFN-a2 | 34.0 | 38 | ||||
RA2159 | IGF-I | 100 | ug/mL | 1 | IFN-a2 | 21.0 | 57 | ||||
RA2159 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 1 | IFN-a2 | 25.0 | 69 | |
RA2159 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 1 | IFN-a2 | 20.0 | 58 | |
RA2159 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 1 | IFN-a2 | 18.0 | 54 | |
RA2159 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 1 | IFN-a2 | 21.5 | 60 | |
RA2159 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 1 | IFN-a2 | 23.0 | 59 | |
RA2159 | 1 | IFN-a2 | 18.0 | 72 | |||||||
N2586 | IGF-I | 100 | ug/mL | 1 | IFN-a2 | 47.5 | 58 |